Piramal Pharma Share Price Target 2025, 2026, 2027, 2028, 2030
Explore Piramal Pharma Share Price Target Tomorrow, 2025, 2026, 2027, 2028, 2029 and 2030 with deep insights into its CDMO dominance, hospital generics, and consumer healthcare businesses. This detailed forecast blends financial performance with expert-backed predictions.
Company Overview 🌟
Piramal Pharma Limited (PPL), a part of the Piramal Group, operates in three core segments: Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics (CHG), and India Consumer Healthcare (ICH). With over 15 manufacturing sites and a presence in 100+ countries, the company generates 68% of its revenue from regulated markets like the US, Europe, and Japan. Through strategic JVs, global expansions, and an asset-light OTC brand strategy, PPL aims to become a global $2B revenue company by FY30.
Piramal Pharma Share Price Target 2025 📊
2025 may see Piramal Pharma benefit from robust CDMO orders and a diversified revenue base. Ongoing expansion in regulated markets, cost efficiency, and product launches in ICH can support stock growth.
| Scenario | Target Price (2025) |
|---|---|
| Bull Case | ₹260 |
| Base Case | ₹235 |
| Bear Case | ₹205 |
Piramal Pharma Share Price Target 2026 📊
In 2026, Piramal Pharma may capitalize on integrated CDMO projects and higher EBITDA margins. Strong CHG pipeline and JV gains from Allergan India are likely to push growth.
| Scenario | Target Price (2026) |
| Bull Case | ₹290 |
| Base Case | ₹255 |
| Bear Case | ₹220 |
Piramal Pharma Share Price Target 2027 📊
With regulatory approvals for new SKUs, margin expansions in ICH, and benefits from biologics via Yapan Bio, Piramal Pharma can witness a performance boost in 2027.
| Scenario | Target Price (2027) |
| Bull Case | ₹320 |
| Base Case | ₹280 |
| Bear Case | ₹240 |
Piramal Pharma Share Price Target 2028 📊
By 2028, the company’s strategic expansions (e.g., Lexington plant) and improved CDMO order book may enhance revenue quality and valuations.
| Scenario | Target Price (2028) |
| Bull Case | ₹355 |
| Base Case | ₹295 |
| Bear Case | ₹250 |
Piramal Pharma Share Price Target 2029 📊
As biologics gain traction and product penetration deepens in regulated markets, Piramal Pharma could hit consistent growth milestones by 2029.
| Scenario | Target Price (2029) |
| Bull Case | ₹390 |
| Base Case | ₹320 |
| Bear Case | ₹275 |
Piramal Pharma Share Price Target 2030 📊
By 2030, Piramal Pharma may emerge as a global pharma powerhouse with diversified business units and a robust global supply chain.
| Scenario | Target Price (2030) |
| Bull Case | ₹430 |
| Base Case | ₹350 |
| Bear Case | ₹295 |
Should I Buy Piramal Pharma Stock?
| Year | Bull Case | Base Case | Bear Case |
| 2025 | ₹260 | ₹235 | ₹205 |
| 2026 | ₹290 | ₹255 | ₹220 |
| 2027 | ₹320 | ₹280 | ₹240 |
| 2028 | ₹355 | ₹295 | ₹250 |
| 2029 | ₹390 | ₹320 | ₹275 |
| 2030 | ₹430 | ₹350 | ₹295 |
Piramal Pharma Financials (2024–2030 Forecast) 💰
| Year | Sales (₹ Cr) | Operating Profit | Net Profit | EPS (₹) |
| 2024 | 8,171 | 1,197 | 18 | 0.13 |
| 2025 | 9,151 | 1,445 | 91 | 0.69 |
| 2026 | 10,180 | 1,725 | 190 | 1.40 |
| 2027 | 11,320 | 1,980 | 275 | 2.05 |
| 2028 | 12,600 | 2,240 | 350 | 2.70 |
| 2029 | 13,850 | 2,480 | 410 | 3.15 |
| 2030 | 15,200 | 2,760 | 480 | 3.85 |
Is Piramal Pharma Stock Good to Buy? 🚀
Bull Case:
- ✅ Strong CDMO pipeline and client base
- ✅ High exposure to regulated markets
- ✅ Biologics growth via Yapan Bio
- ✅ Cost-efficient expansion strategy
Bear Case:
- ⚠️ Slower-than-expected global regulatory approvals
- ⚠️ Overdependence on few geographies
- ⚠️ Margin pressure in ICH segment
- ⚠️ Leadership changes affecting momentum
Conclusion
Piramal Pharma Ltd offers a compelling mix of innovation, international expansion, and strategic execution. Investors looking for long-term growth in healthcare and pharma may consider the stock, while staying mindful of regulatory and margin risks.
FAQs 🤔
1. What is Piramal Pharma share price target for tomorrow?
Bullish case target is ₹212 with support near ₹203.0
2. Is Piramal Pharma a good stock for 2025?
In the base case, 2025 target is ₹235. Long-term potential looks promising.
3. What are Piramal Pharma growth drivers?
CDMO expansions, biologics, ICH brand scaling, and JV earnings.
4. What is the 2030 target for Piramal Pharma?
Bullish scenario sees Piramal Pharma at ₹430 by 2030.
Similar Stocks:
- Reliance Power Share Price Target 2025, 2026, 2027, 2028, 2029, 2030
- Jubilant Pharmova Share Price Target 2025, 2026, 2027, 2028, 2029, 2030
External Link:
